Juniper Pharmaceuticals Inc (JNP) Stake Lowered by Macquarie Group Ltd.

Macquarie Group Ltd. lessened its position in Juniper Pharmaceuticals Inc (NASDAQ:JNP) by 78.2% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 14,758 shares of the specialty pharmaceutical company’s stock after selling 52,937 shares during the period. Macquarie Group Ltd.’s holdings in Juniper Pharmaceuticals were worth $128,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Spark Investment Management LLC increased its holdings in shares of Juniper Pharmaceuticals by 53.5% in the 2nd quarter. Spark Investment Management LLC now owns 52,500 shares of the specialty pharmaceutical company’s stock valued at $456,000 after purchasing an additional 18,300 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Juniper Pharmaceuticals by 51.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 225,919 shares of the specialty pharmaceutical company’s stock valued at $1,965,000 after purchasing an additional 76,614 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of Juniper Pharmaceuticals by 80.5% in the 2nd quarter. Acadian Asset Management LLC now owns 275,506 shares of the specialty pharmaceutical company’s stock valued at $2,397,000 after purchasing an additional 122,893 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Juniper Pharmaceuticals by 13.9% in the 2nd quarter. Renaissance Technologies LLC now owns 752,173 shares of the specialty pharmaceutical company’s stock valued at $6,544,000 after purchasing an additional 91,623 shares in the last quarter. Institutional investors own 45.56% of the company’s stock.

Shares of JNP opened at $11.50 on Friday. The company has a quick ratio of 2.18, a current ratio of 2.57 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $129.89 million, a PE ratio of -76.67 and a beta of 0.66. Juniper Pharmaceuticals Inc has a 52-week low of $4.30 and a 52-week high of $13.25.

Juniper Pharmaceuticals (NASDAQ:JNP) last announced its quarterly earnings results on Thursday, August 9th. The specialty pharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.04 by ($0.18). The company had revenue of $15.31 million during the quarter, compared to analysts’ expectations of $16.30 million. Juniper Pharmaceuticals had a negative net margin of 1.77% and a negative return on equity of 1.09%. On average, equities research analysts forecast that Juniper Pharmaceuticals Inc will post 0.15 EPS for the current fiscal year.

Juniper Pharmaceuticals Profile

Juniper Pharmaceuticals, Inc, a diversified healthcare company, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in women's health. It operates in two segments, Product and Service. The company develops its products utilizing its proprietary drug delivery technologies, which include bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa to achieve sustained and controlled delivery of active drug product; and a novel intravaginal ring technology.

Further Reading: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Want to see what other hedge funds are holding JNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juniper Pharmaceuticals Inc (NASDAQ:JNP).

Institutional Ownership by Quarter for Juniper Pharmaceuticals (NASDAQ:JNP)

Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply